Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,376 total articles
Planet Labs ($31.38) is a volatile but improving business: daily Earth-observation data, accelerating revenue trends, and positive free cash flow. The market is pricing steep growth expectations (P/S ~33), but a recent sector rotation and pullback create a tactical buying opportunity. Trade Plan: enter at $31.00, stop $27.00, primary target $48.00 …
Upstart looks like a classic growth-recovery trade: strong top-line momentum, improving profitability, and a lower short-term valuation than its 2025 highs. We like the risk/reward here with an entry near $34.80, a $45 target for the rally window and a $30 stop to limit downside if funding or Model 22 litigation issues resurface.
Contango Silver & Gold is transforming from a collection of assets into an operational platform after acquiring Lucky Shot and delivering extremely high-grade drill results. With a market cap near $531m, manageable leverage and heavy recent insider-driven M&A activity, this trade idea takes a constructive stance: buy on constructive technicals and …
Perdoceo Education has delivered meaningful earnings and free cash flow expansion while keeping debt nearly non-existent. At about $34.45 and ~13x earnings, the stock looks like a reasonable value pick with multiple near-term catalysts. We upgrade to a Buy and lay out an actionable swing trade with clear entry, stop and target.
ExxonMobil's combination of durable free cash flow, a ~3% yield, low leverage, and pipeline of growth-led projects (Guyana, Permian, LNG) creates a favorable risk-reward setup near $137. I am upgrading to a buy and re-entering with a measured long-term trade plan: entry $137.00, target $165.00, stop loss $125.00, horizon 180 trading days.
MTY Food Group (MTY) is a franchising-and-acquisition-led restaurant roll-up trading at a valuation below its historical average. With recurring franchise cash flows, a modest net cash position and multiple integration levers to drive margin expansion, MTY looks like a pragmatic mid-term long. This trade idea lays out a clear entry, stop and target…
Rocket Lab's $8 billion Iridium acquisition is a tectonic shift: it pairs a growing launch and spacecraft manufacturer with an established global satellite network. The deal amplifies recurring revenue potential, widens addressable markets (IoT, aviation, maritime, positioning) and accelerates vertical integration. The stock is richly priced today,…
Nuveen New York Quality Municipal Income Fund (NAN) offers an attractive monthly distribution (yield ~7.34%), trading near its 52-week high with bullish technicals. For income-oriented investors who can tolerate CEF volatility and municipal-credit risk, a long trade with a clear stop and target offers a favorable risk/reward over a 180-trading-day …
Kymera is trading with a biotech premium but also with cash and clinical catalysts in H2 2026 that could re-rate the stock. We lay out a long trade plan to capture the KT-579 Phase 1 readout and ongoing KT-621 momentum while managing binary clinical risk.
Futu (FUTU) has been pummeled by regulatory headlines and class-action filings tied to a May 22, 2026 crackdown on cross-border securities solicitation. That pain looks largely priced in: the stock trades at $95.09 with a market cap near $12.5B, a PE of ~11 and a 2.55% yield. With ECM and enterprise service initiatives beginning to show traction an…
TSS, Inc. is a small-cap integrator for data-center and mission-critical facilities that has pulled revenue and EBITDA higher as AI customers push capacity and require on-site integration. With recent quarterly momentum and 2026 adjusted EBITDA guidance of $20-22M, TSS is positioned to re-rate if execution continues. This trade outlines a mid-term …
Travere (TVTX) now looks like more than a single-product biotech. With Filspari (sparsentan) gaining traction in rare kidney indications and a market cap of ~$5.3B, the setup favors a long-biased trade for patient, risk-aware investors. This idea lays out a clear entry, stop and target, and the reasons to own TVTX over the next 180 trading days.
Versigent (VGNT) combines proprietary electrical architecture for vehicles with exposure to energy storage and electrification trends. At $40.16 and a market cap near $2.9B, the shares trade at an attractive P/E (~5.4) while technicals show near-term weakness. For disciplined traders, a long swing position sized around a mid-risk allocation offers …
Kraft Heinz (KHC) looks attractive as a dividend-oriented, value trade. The stock yields ~6.4%, trades below book at ~0.72x, and is supported by bullish technicals (price > 10/20/50-day averages, RSI ~65, MACD positive). Free cash flow covers the dividend comfortably. We'll lay out an actionable entry, stop and target with a 180-trading-day positio…
National Health Investors (NHI) is a cash-generative REIT focused on senior housing and medical assets. With a 4.75% yield, stable free cash flow, and technical momentum, NHI offers a pragmatic long trade: buy at $77.00, target $88.00, stop $70.00. The trade banks on accelerating senior-housing demand, steady dividend support, and a reasonable valu…
Sibanye Stillwater (SBSW) offers a mid-term swing opportunity. The shares trade near $9 on a flattened post-rally pullback, with a $6.34B market cap, a 2.8% yield and clear catalysts from a potent platinum rally and cost discipline. Technicals and short interest show limited downside pressure; I recommend a defined-entry long with a $13.50 target a…
KeyCorp's May repurchase authorization and steady dividend make the bank an attractive income-plus-capital-gain trade. At around $23, the shares price in modest multiples (P/E ~13.8, P/B ~1.24) while free cash flow and a sensible balance sheet support buybacks and dividends. This trade targets upside from repurchase execution and event-driven clari…
Insulet’s Omnipod franchise remains a durable growth engine despite a manufacturing recall that reset sentiment. At $164.58 the stock prices in a premium multiple (P/E ~37, P/S ~3.8) but also delivers strong free cash flow ($399.9m) and high returns on equity (23%). For traders who want exposure to recovery in device adoption, a controlled long wit…
PagSeguro’s mix of low-risk deposits, merchant POS hardware and growing digital accounts is set to benefit disproportionately when Brazil enters its next rate-cut cycle. At a $2.53B market cap, single-digit P/E and a yield near 0.44%, the stock offers an asymmetric risk-reward for a long-term trade timed to monetary easing.
<p>Embraer is showing the operational footprints and order momentum that can re-light investor interest. This trade targets a mid-term rebound that captures higher production cadence, services revenue kicking in and sentiment re-rating while keeping a disciplined stop to limit downside.</p>
Brookfield Asset Management (BAM) is trading near $45.87 after a pullback from last year’s highs. The business mixes fee-bearing asset management with growing exposure to renewable and infrastructure cash flows, producing $2.305B in free cash flow and a ~4.1% yield today. Short-term momentum and technicals look noisy, but a structured long trade wi…
ON Semiconductor recently sold off after the $7B Synaptics deal and dilution headline. The market has focused on near-term dilution while under-appreciating two durable, higher-margin end markets forming around 800V-1200V silicon carbide power for AI data centers and the Physical AI transition at the edge. ON's balance sheet, cash flow generation a…
Vita Coco (COCO) is the clear leader in U.S. coconut water with ~51-52% share, growing top-line and margins while guiding higher for 2026. The shares have pulled back into an attractive setup after momentum cooled; this trade buys a proven category leader at a defensible price with a clear stop and target.
Voyager Therapeutics has moved beyond single-program risk into a platform story: new AAV capsids that penetrate the blood-brain barrier, multiple Alzheimer’s-focused assets, and a stretched but still visible cash runway. The technicals and short-interest dynamics make a defined-risk long trade attractive over the next ~45 trading days, but executio…
CVR Energy ($CVI) trades at an enterprise value of ~$4.14B and an EV/EBITDA of 7.1x. With free cash flow of $68M last reported and a modest $0.10 quarterly distribution, CVR is a cash-generative refiner exposed to crack spread dynamics. We see a mid-term trade to capture underpriced margin upside as product-crude spreads remain elevated and refiner…
